Logo image of ALMNG.PA

MADVERTISE (ALMNG.PA) Stock Fundamental Analysis

EPA:ALMNG - Euronext Paris - Matif - FR0010812230 - Common Stock - Currency: EUR

0.391  +0.03 (+8.61%)

Fundamental Rating

0

We assign a fundamental rating of 0 out of 10 to ALMNG. ALMNG was compared to 57 industry peers in the Media industry. ALMNG may be in some trouble as it scores bad on both profitability and health. ALMNG does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year ALMNG has reported negative net income.
ALMNG.PA Yearly Net Income VS EBIT VS OCF VS FCFALMNG.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 0 -1M -2M -3M

1.2 Ratios

Industry RankSector Rank
ROA -19.49%
ROE N/A
ROIC 48.77%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ALMNG.PA Yearly ROA, ROE, ROICALMNG.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 0 200 -200 400 600 800 1K

1.3 Margins

Industry RankSector Rank
OM -5.11%
PM (TTM) -9.75%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ALMNG.PA Yearly Profit, Operating, Gross MarginsALMNG.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 0 10 -10 20 -20

More info and screens

1

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so ALMNG is creating value.
The number of shares outstanding for ALMNG has been increased compared to 1 year ago.
The debt/assets ratio for ALMNG is higher compared to a year ago.
ALMNG.PA Yearly Shares OutstandingALMNG.PA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2M 4M 6M 8M 10M
ALMNG.PA Yearly Total Debt VS Total AssetsALMNG.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 5M 10M 15M

2.2 Solvency

Based on the Altman-Z score of -0.10, we must say that ALMNG is in the distress zone and has some risk of bankruptcy.
ALMNG has a Debt/Equity ratio of -0.65. This is a healthy value indicating a solid balance between debt and equity.
Industry RankSector Rank
Debt/Equity -0.65
Debt/FCF N/A
Altman-Z -0.1
ROIC/WACC6.74
WACC7.24%
ALMNG.PA Yearly LT Debt VS Equity VS FCFALMNG.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 0 2M -2M -4M

2.3 Liquidity

ALMNG has a Current Ratio of 0.57. This is a bad value and indicates that ALMNG is not financially healthy enough and could expect problems in meeting its short term obligations.
ALMNG has a Quick Ratio of 0.57. This is a bad value and indicates that ALMNG is not financially healthy enough and could expect problems in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 0.57
Quick Ratio 0.57
ALMNG.PA Yearly Current Assets VS Current LiabilitesALMNG.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2M 4M 6M 8M 10M

More info and screens

0

3. Growth

3.1 Past

ALMNG shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -35.33%.
The Revenue has decreased by -1.68% in the past year.
Measured over the past years, ALMNG shows a decrease in Revenue. The Revenue has been decreasing by -2.22% on average per year.
EPS 1Y (TTM)-35.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-61.53%
Revenue 1Y (TTM)-1.68%
Revenue growth 3Y-8.26%
Revenue growth 5Y-2.22%
Sales Q2Q%3.74%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ALMNG.PA Yearly Revenue VS EstimatesALMNG.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 5M 10M 15M
ALMNG.PA Yearly EPS VS EstimatesALMNG.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 -0.02 -0.04 -0.06 -0.08 -0.1

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ALMNG reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ALMNG.PA Price Earnings VS Forward Price EarningsALMNG.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA -52.19
ALMNG.PA Per share dataALMNG.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 0.6 0.8 1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ALMNG!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MADVERTISE

EPA:ALMNG (7/28/2022, 7:00:00 PM)

0.391

+0.03 (+8.61%)

Chartmill FA Rating
GICS SectorCommunication Services
GICS IndustryGroupMedia & Entertainment
GICS IndustryMedia
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst OwnersN/A
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap5.27M
Analysts84.44
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.37
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA -52.19
EPS(TTM)-0.1
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS1.05
BVpS-0.32
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -19.49%
ROE N/A
ROCE N/A
ROIC 48.77%
ROICexc N/A
ROICexgc 16.72%
OM -5.11%
PM (TTM) -9.75%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y0%
ROICexcg growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover2
Health
Industry RankSector Rank
Debt/Equity -0.65
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.57
Quick Ratio 0.57
Altman-Z -0.1
F-Score1
WACC7.24%
ROIC/WACC6.74
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-35.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-61.53%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-1.68%
Revenue growth 3Y-8.26%
Revenue growth 5Y-2.22%
Sales Q2Q%3.74%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A